Navigation Links
DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
Date:12/19/2007

LA JOLLA, Calif., Dec 19 /PRNewswire/ -- DermTech, Inc., a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, announced that it has been issued Patent No. 7,297,480 by the United States Patent and Trademark Office. The patent, entitled: "Method for Detection of Melanoma", includes claims focused on non-invasive methods for detecting early-stage melanoma and for staging, and claims for monitoring melanoma in a subject.

The patent claims the use of DermTech's "tape stripping" technology for the purposes of detecting, staging and monitoring melanoma. The methods claimed in the patent focus on the use of DermTech's EGIR (Epidermal Genetic Information Retrieval, a skin sampling technique known as "tape stripping" in combination with a molecular diagnostic assay). Specifically, adhesive tape is placed over a lesion suspicious for melanoma and then removed to harvest the top layer of skin cells. The RNA is extracted and analyzed to determine and compare the level of a key melanoma marker, Interleukin-2 Receptor 1 (IL-2 R1), with the level in a normal skin control sample. A decrease in IL-2 R1 is indicative of early-stage melanoma. The patent also claims the use of evaluating additional biomarkers based upon differences in gene expression such that a change in these messenger RNAs is indicative of late-stage melanoma. The ability to detect, stage and monitor disease is critical for improved clinical outcomes.

"DermTech welcomes the issuance of this patent as it will allow us to move forward and more fully develop and position our core EGIR technology for the staging as well as the detection, of melanoma," said George Schwartz, CEO, DermTech. "This patent is an important addition to our intellectual property portfolio."

The incidence rate of malignant melanoma is increasing faster than any other cancer. Treatment involves surgical excision of the primary lesion, and vigilant monitoring to detect recurrence. The methods for detecting malignant melanoma described in DermTech's newly issued patent can serve as the basis for therapeutic decisions, saving many lives and reducing costs by avoiding unnecessary excisions and biopsies.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens derived from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information, visit http://www.dermtech.com

Contacts:

DermTech

George Schwartz

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
2. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... ... in regenerative medicine, has announced a new agreement with Singapore-based Global Stem Cells ... physicians from the Philippines, Thailand and Singapore in the latest adipose and bone ...
(Date:2/9/2016)... ... 2016 , ... Date and time: March 1, 2016, 5:30 ... Biotechnology Center of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , ... an open house for participants to learn about a new Master of Biomedical ...
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry has ... publishing is one of the popular publication models that has received wider acknowledgement ... and 3000+ International Conferences across the globe, OMICS International is all ...
(Date:2/9/2016)... 9, 2016 Three-Year Initiative Supports Next ... Take Part in Life-Changing Camp Experiences ... to positively affect the lives of children born with rare diseases, ... SHPG ) is announcing a new initiative designed to positively ... as the future of rare disease care. --> To ...
Breaking Biology Technology:
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Facial Recognition ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced ... Recognition Market 2016-2020" report to their ... ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):